These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 30470647)

  • 21. Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey.
    Hendricksen K; Aziz A; Bes P; Chun FK; Dobruch J; Kluth LA; Gontero P; Necchi A; Noon AP; van Rhijn BWG; Rink M; Roghmann F; Rouprêt M; Seiler R; Shariat SF; Qvick B; Babjuk M; Xylinas E;
    Eur Urol Focus; 2019 Jul; 5(4):681-688. PubMed ID: 29074050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation of the CUETO scoring model for predicting recurrence and progression in T1G3 urothelial carcinoma of the bladder.
    Krajewski W; Rodríguez-Faba O; Breda A; Pisano F; Poletajew S; Tukiendorf A; Zdrojowy R; Kołodziej A; Palou J
    Actas Urol Esp (Engl Ed); 2019 Oct; 43(8):445-451. PubMed ID: 31155372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction tools in non-muscle invasive bladder cancer.
    Zamboni S; Moschini M; Simeone C; Antonelli A; Mattei A; Baumeister P; Xylinas E; Hakenberg OW; Aziz A
    Transl Androl Urol; 2019 Feb; 8(1):39-45. PubMed ID: 30976567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
    Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
    Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Performance of the EORTC and CUETO Models to Predict Recurrence and Progression in High-risk Non-muscle-invasive Bladder Cancer Patients.
    Pazır Y; Esmeray A; Gelmis M; Caglar U; Ozgor F; Sarılar O; Akbulut F
    Urol J; 2024 May; 21(3):169-174. PubMed ID: 38493314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review.
    Soukup V; Čapoun O; Cohen D; Hernández V; Babjuk M; Burger M; Compérat E; Gontero P; Lam T; MacLennan S; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Yuan Y; Zigeuner R
    Eur Urol; 2017 Nov; 72(5):801-813. PubMed ID: 28457661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting recurrence and progression in Chinese patients with nonmuscle-invasive bladder cancer using EORTC and CUETO scoring models.
    Xu T; Zhu Z; Zhang X; Wang X; Zhong S; Zhang M; Shen Z
    Urology; 2013 Aug; 82(2):387-93. PubMed ID: 23759377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.
    Fernandez-Gomez J; Madero R; Solsona E; Unda M; Martinez-Piñeiro L; Gonzalez M; Portillo J; Ojea A; Pertusa C; Rodriguez-Molina J; Camacho JE; Rabadan M; Astobieta A; Montesinos M; Isorna S; Muntañola P; Gimeno A; Blas M; Martinez-Piñeiro JA
    J Urol; 2009 Nov; 182(5):2195-203. PubMed ID: 19758621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic Significance of the Neutrophil-to-Lymphocyte Ratio in Patients with Non-Muscle Invasive Bladder Cancer treated with Intravesical Bacillus Calmette-Guérin and the Relationship with the CUETO Scoring Model.
    Chung JW; Kim JW; Lee EH; Chun SY; Park DJ; Byeon KH; Choi SH; Lee JN; Kim BS; Kim HT; Yoo ES; Kwon TG; Ha YS; Kim TH
    Urol J; 2021 Oct; 19(4):281-288. PubMed ID: 34655075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer.
    Rieken M; Shariat SF; Kluth L; Crivelli JJ; Abufaraj M; Foerster B; Mari A; Ilijazi D; Karakiewicz PI; Babjuk M; Gönen M; Xylinas E
    Urol Oncol; 2018 Jan; 36(1):8.e17-8.e24. PubMed ID: 28947304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
    Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
    BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. External validation of the EORTC and NCCN bladder cancer recurrence and progression risk calculators in a U.S. community-based health system.
    Leo MC; McMullen CK; O'Keeffe-Rosetti M; Weinmann S; Garg T; Nielsen ME
    Urol Oncol; 2020 Feb; 38(2):39.e21-39.e27. PubMed ID: 31711836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of non-muscle-invasive bladder cancer risk stratification updated in the 2021 European Association of Urology guidelines.
    Miyake M; Kitamura H; Nishimura N; Miyamoto T; Nakahama T; Fujii T; Matsumoto H; Matsuyama H; Yonemori M; Enokida H; Taoka R; Kobayashi T; Kojima T; Matsui Y; Nishiyama N; Nishiyama H; Fujimoto K;
    BJUI Compass; 2024 Mar; 5(2):269-280. PubMed ID: 38371197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting recurrence and progression of non-muscle-invasive bladder cancer in Korean patients: a comparison of the EORTC and CUETO models.
    Choi SY; Ryu JH; Chang IH; Kim TH; Myung SC; Moon YT; Kim KD; Kim JW
    Korean J Urol; 2014 Oct; 55(10):643-9. PubMed ID: 25324946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-muscle Invasive Bladder Cancer in Asia.
    Ieda T; Muto S; Shimizu F; Taguri M; Yanada S; Kitamura K; Terai K; Saito K; Ogishima T; Nagata M; Ide H; Okegawa T; Wakumoto Y; Sakamoto Y; Tsujimura A; Yamaguchi R; Nutahara K; Horie S
    EBioMedicine; 2016 Oct; 12():98-104. PubMed ID: 27614395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum.
    Beijert IJ; Hentschel AE; Bründl J; Compérat EM; Plass K; Rodríguez O; Subiela Henríquez JD; Hernández V; de la Peña E; Alemany I; Turturica D; Pisano F; Soria F; Čapoun O; Bauerová L; Pešl M; Bruins HM; Runneboom W; Herdegen S; Breyer J; Brisuda A; Calatrava A; Rubio-Briones J; Seles M; Mannweiler S; Bosschieter J; Kusuma VRM; Ashabere D; Huebner N; Cotte J; Mertens LS; Claps F; Masson-Lecomte A; Liedberg F; Cohen D; Lunelli L; Cussenot O; El Sheikh S; Volanis D; Côté JF; Rouprêt M; Haitel A; Shariat SF; Mostafid AH; Nieuwenhuijzen JA; Zigeuner R; Dominguez-Escrig JL; Hacek J; Zlotta AR; Burger M; Evert M; Hulsbergen-van de Kaa CA; van der Heijden AG; Kiemeney LALM; Soukup V; Molinaro L; Gontero P; Llorente C; Algaba F; Palou J; N'Dow J; Ribal MJ; van der Kwast TH; Babjuk M; Sylvester RJ; van Rhijn BWG
    Eur Urol Oncol; 2023 Apr; 6(2):214-221. PubMed ID: 36670042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing the Predictive Accuracy of EORTC, CUETO and EAU Risk Stratification Models for High-Grade Recurrence and Progression after Bacillus Calmette-Guérin Therapy in Non-Muscle-Invasive Bladder Cancer.
    Ślusarczyk A; Garbas K; Pustuła P; Zapała Ł; Radziszewski P
    Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCG.
    Contieri R; Hurle R; Paciotti M; Casale P; Saita A; Porpiglia F; Fiori C; Barone B; Crocetto F; Lucarelli G; Busetto GM; Del Giudice F; Maggi M; Cantiello F; Damiano R; Borghesi M; Bove P; Bertolo R; Papalia R; Mari A; Luzzago S; Mistretta FA; Soria F; Gontero P; Marchioni M; LA Civita E; Terracciano D; Russo GI; Schips L; Perdona S; Mirone V; Tataru OS; Musi G; Vartolomei MD; Autorino R; Montanari E; DE Cobelli O; Ferro M
    Minerva Urol Nephrol; 2023 Apr; 75(2):180-187. PubMed ID: 36197700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.